The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors
Open accessAbstract
Studies of the anti-tumor activity of TNF-alpha in vivo have been hampered by the need to administer systemically toxic doses of the cytokine to obtain a curative response. To facilitate studies of the effect of high local concentrations of TNF-alpha on tumor growth and host immunity, a newly induced murine sarcoma was transduced with the gene for human TNF-alpha and the biologic characteristics of these cells were examined. We identified high and low TNF-producing tumor clones which exhibited stable TNF secretion over time. Significant amounts of membrane associated TNF were found in a high-TNF producing clone as well. No difference in the in vitro growth rates between TNF-producing and nonproducing cell lines was observed. In contrast, in vivo studies demonstrate that although unmodified parental tumor cells grew progressively when implanted s.c. in animals, tumor cells transduced with the TNF gene were found to regress in a significant number of animals after an initial phase of growth. This effect correlated with the amount of TNF produced and could be blocked with a specific anti-TNF antibody. Regressions of TNF-producing cells occurred in the absence of any demonstrable toxicity in the animals bearing these tumors. TNF-producing tumor cells could function in a paracrine fashion by inhibiting the growth of unmodified, parental tumor cells implanted at the same site. The ability of tumor cells to regress was abrogated by in vivo depletion of CD4+ or CD8+ T cell subsets and animals that had experienced regression of TNF-producing tumors rejected subsequent challenges of parental tumor. Our studies thus show that tumor cells elaborating high local concentrations of TNF regress in the absence of toxicity in the host and that this process requires the existence of intact host immunity. Studies of the lymphocytes infiltrating the gene modified tumors and attempts to use TNF gene modified tumor infiltrating lymphocytes to deliver high local concentrations of TNF to the tumor site without inducing systemic toxicity are underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figari, I. S., Palladino, M. A., & Shepard, H. M. (1985) · Science · doi:10.1126/science.3933111 · Cited by 1,580
DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.
Wigler, M., Pellicer, A., Silverstein, S., Axel, R., Urlaub, G., & Chasin, L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.3.1373 · Cited by 1,279
Kriegler, M., Perez, C., DeFay, K., Albert, I., & Lu, S. D. (1988) · Cell · doi:10.1016/0092-8674(88)90486-2 · Cited by 1,102
Self-citationExperience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Self-citationFearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Shalaby, M. R., Aggarwal, B. B., Rinderknecht, E., Svedersky, L. P., Finkle, B. S., & Palladino, M. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.3.2069 · Cited by 913
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., & Waldmann, H. (1984) · Nature · doi:10.1038/312548a0 · Cited by 863
Murine interleukin-4 displays potent anti-tumor activity in vivo
Tepper, R. I., Pattengale, P. K., & Leder, P. (1989) · Cell · doi:10.1016/0092-8674(89)90925-2 · Cited by 778
Philip, R., & Epstein, L. B. (1986) · Nature · doi:10.1038/323086a0 · Cited by 767
Tumors secreting human TNF/cachectin induce cachexia in mice
Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A., & Socher, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90028-6 · Cited by 640
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.991 · Cited by 494
Scheurich, P., Thoma, B., Ucer, U., & Pfizenmaier, K. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.6.1786 · Cited by 492
Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., & Rowley, D. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1486 · Cited by 403
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials
Topalian, S. L., Muul, L. M., Solomon, D., & Rosenberg, S. A. (1987) · Journal of Immunological Methods · doi:10.1016/s0022-1759(87)80018-2 · Cited by 362
Self-citationMonoclonal antibodies to promote marrow engraftment and tissue graft tolerance
Cobbold, S. P., Martin, G., Qin, S., & Waldmann, H. (1986) · Nature · doi:10.1038/323164a0 · Cited by 335
Haranaka, K., Satomi, N., & Sakurai, A. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340219 · Cited by 311
Asher, A., Mulé, J. J., Reichert, C. M., Shiloni, E., & Rosenberg, S. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.963 · Cited by 289
Self-citationWatanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., & Sakata, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9456 · Cited by 282
Havell, E. A., Fiers, W., & North, R. J. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1067 · Cited by 276
Effect of tumour necrosis factor on cultured human melanoma cells
HELSON, L., GREEN, S., CARSWELL, E., & OLD, L. J. (1975) · Nature · doi:10.1038/258731a0 · Cited by 238
Antitumor activity of recombinant interleukin 6 in mice.
Mulé, J. J., McIntosh, J. K., Jablons, D. M., & Rosenberg, S. A. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.3.629 · Cited by 227
Self-citationPalladino, M. A., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., et al. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.11.4023 · Cited by 201
Owen‐Schaub, L. B., Gutterman, J. U., & Grimm, E. A. (1988) · PubMed · Cited by 176
Kasid, A., Morecki, S., Aebersold, P. M., Cornetta, K. G., Culver, K. W., Freeman, S., Director, E. P., Lotze, M. T., Blaese, R. M., & Anderson, W. F. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.1.473 · Cited by 145
Self-citationKinkhabwala, M. M., Sehajpal, P. K., Skolnik, E. Y., Smith, D. R., Sharma, V. K., Vlassara, H., Cerami, A., & Suthanthiran, M. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.3.941 · Cited by 132
Immunomodulatory properties of recombinant murine and human tumor necrosis factor.
Talmadge, J. E., Phillips, H., Schneider, M., Rowe, T., Pennington, R. M., Bowersox, O., & Lenz, B. F. (1988) · PubMed · Cited by 129
Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.
Creasey, A. A., Reynolds, M., & Laird, W. (1986) · PubMed · Cited by 123
McIntosh, J. K., Jablons, D. M., Mulé, J. J., Nordan, R. P., Rudikoff, S., Lotze, M. T., & Rosenberg, S. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.1.162 · Cited by 115
Self-citationModulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
Weber, J. S., & Rosenberg, S. A. (1988) · PubMed · Cited by 103
Self-citationBringman, T. S., & Aggarwal, B. B. (1987) · Hybridoma · doi:10.1089/hyb.1987.6.489 · Cited by 61
Pulmonary Metastases From Autochthonous 3-Methylcholanthrene-Induced Murine Tumors
Wexler, H., & Rosenberg, S. A. (1979) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/63.6.1393 · Cited by 19
Self-citation
Cited by
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Human gene therapy comes of age
Miller, A. D. (1992) · Nature · doi:10.1038/357455a0 · Cited by 908
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 635
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000) · Nature Biotechnology · doi:10.1038/81183 · Cited by 419
Metadata
- Authors
- Asher, A. L., Mulé, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., & Rosenberg, S. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-05-01
- Volume
- 146
- Issue
- 9
- Pages
- 3227-3234
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1488558875
- Cited by
- 281
- References
- 33
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.